BioMotiv, Biogen Form Strategic Partnership

BioMotiv, LLC, the therapeutic accelerator company associated with The Harrington Project for Discovery & Development has announced that it has entered into a strategic partnership with Biogen. 

Biogen has committed to invest $15 million in BioMotiv over five years, providing Biogen with exclusive rights relating to neuroscience programs sourced and developed by BioMotiv.

 “Biogen is the leading company for developing novel neuroscience therapeutics,” said Baiju R. Shah, Chief Executive Officer of BioMotiv. “This partnership completes a platform to advance novel medicines that address some of the most complex medical challenges.” 

BioMotiv is the for-profit component of The Harrington Project for Discovery & Development. Launched in 2012, The Harrington Project is a $250 million international initiative with an aim of identifying, funding, and rapidly advancing the development of medical breakthroughs from innovative physician-scientists throughout the US and UK. In pursuing its mission, The Harrington Project also works in partnership with disease foundations such as the Alzheimer’s Drug Discovery Foundation. It is unique in focusing on physician scientists and providing comprehensive expert resources and funding to advance these discoveries into innovative, new medicines. 

“Biogen is committed to working with the world’s leading clinicians and scientists to accelerate the discovery of novel neuroscience medicines,” said Spyros Artavanis-Tsakonas, Senior Vice President and Chief Scientific Officer at Biogen. “Partnering with BioMotiv allows us to source programs through the innovative model of The Harrington Project, and to develop breakthrough therapies that have the potential to provide benefits for patients.”